| 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | 美因基因有限公司 | | 股份代號 | 06667 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月31日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.15 RMB | | 股東批准日期 | 2026年6月26日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | | 除淨日 | 有待公佈 | | 為 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 截 至2025年12月31日止年度的 年度業績公告 美 因 基 因 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2025年12月31日 止 年 度（「報告期」）的 綜 合 業 績。 於 本 公 告 中，「我 們」指 本 公 司 及（如 文 義 所 指）本 集 團。本 公 告 所 載 若 干 金 額 及 百 分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之處，皆為 約 整 所 致。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 本 公 司 刊 發 日 期 為2022年6月 10日的招股章程所界定者具有相同涵義。 * 僅供識別 – 1 – 業務回顧及展望 業績回顧 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 盈利警告 本公告由美因基因有限公司（「本公司」，連同其附屬公司為「本集團」）根據香港聯合交 易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及期貨條 例第XIVA部項下的內幕消息條文（定義見上市規則）作出。 本公司董事（「董事」）會（「董事會」）謹此告知本公司股東（「股東」）及本公司潛在投資 者，基於對本集團截至2025年12月31日止年度之未經審核綜合管理賬目的初步評估及董 事會現時可得最新資料，本集團預期(i)截至2025年1 2月3 1日止年度的收入約為 人民幣240.0百萬元至人民幣250.0百萬元，而截至2024年12月31日止年度的收入為人民 幣164.2百萬元；及(ii)截至2025年12月31日止年度本集團擁有人應佔利潤約為人民幣 ...

董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 承董事會命 美因基因有限公司 執行董事兼主席 林琳 香港，2026年3月19日 於本公告日期，本公司執行董事為俞熔博士、林琳女士及姜晶女士；非執行董事為郭美 玲女士；及獨立非執行董事為張影博士、賈慶豐先生及謝丹博士。 * 僅供識別 美因基因有限公司（「本公司」，連同其附屬公司「本集團」）董事（「董事」）會（「董事 會」）兹通告謹定於2026年3月31日（星期二）舉行董事會會議，以考慮及通過本集團截至 2025年12月31日止年度的全年業績公告及其發佈，及建議末期股息（如有），以及處理其 他事項。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 美因基因有限公司 | | | | | | 呈交日期: | 2026年3月3日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 06667 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 224,300,200 0 224,300,200 增加 / 減少 (-) 0 0 本月底結存 224,300,200 0 224,300,200 足夠公眾持股量的確認(註4) | 證券代號 (如上市) | 06667 | 說明 | | | | | | | | --- ...

格隆汇2月27日丨美因基因(06667.HK)发布公告，该公司的股份将于今天(27/2/2026)上午九时正起恢复 买卖。 ...

Core Viewpoint - The company, 美因基因 (06667), has met all resumption guidelines and has applied to resume trading of its shares on the Hong Kong Stock Exchange starting from February 27, 2026, at 9:00 AM [1] Group 1 - The company has successfully achieved compliance with all necessary resumption conditions [1] - The application for resumption of trading has been officially submitted [1]

智通财经APP讯，美因基因(06667)发布公告，公司已达成所有复牌指引。公司已申请于2026年2月27日 上午9时正起恢复公司股份于联交所买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 達成所有復牌指引 及 恢復買賣 本公司的財務顧問 滙生國際資本有限公司 緒言 本公告乃由美因基因有限公司（「本公司」），連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條以及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 –1– 茲提述本公司日期為2025年4月1日、2025年4月22日、2025年4月30日、2025年5月5日、 2025年5月30日、2025年6月30日、2025年8月29日、2025年9月30日、2025年11月10日、 2025年12月31日、2026年1月12日、2026年1月30日、2026年2月4日及2026年2月9日（「該等 公告」 ...

Genetic Testing and Diagnostic Solutions - As of June 30, 2025, the company has conducted over 24 million genetic tests, making it the largest consumer genetic testing platform in China by cumulative testing volume [11]. - The company has developed 114 commercialized testing solutions for consumer genetic testing and cancer screening, with 94 of these being independently developed [12]. - The company offers a range of services, including brain health assessment, nutritional absorption capability assessment, and comprehensive cancer risk assessment [12]. - The company is developing eight in vitro diagnostic (IVD) pipeline products, including three consumer-grade genetic testing kits for assessing risks of various diseases, with regulatory approval expected by 2025 [13]. - The ApoE genetic testing kit, which assesses Alzheimer's disease risk, utilizes a blood nucleic acid non-extraction technology, reducing testing costs and time [16]. - The folate metabolism assessment kit provides guidance for pregnant women to prevent neonatal defects and assess risks of cardiovascular diseases, with regulatory approval expected by 2025 [17]. - The Alzheimer's disease screening kit is based on plasma miRNA biomarkers, with clinical validation involving at least 1,500 samples and collaboration with multiple hospitals [18]. - The colorectal cancer screening kit is based on plasma DNA methylation biomarkers, with preliminary screening completed and collaboration with three hospitals for clinical validation [20]. - The gastric cancer screening kit also utilizes plasma DNA methylation biomarkers, with similar development and validation processes as the colorectal cancer kit [24]. - The BRCA1/BRCA2 genetic mutation testing kit has completed formulation development and established a database of tens of thousands of mutation sites [29]. - The company anticipates developing qPCR and NGS testing kits for various diseases, with expected sensitivity and specificity greater than 90% [22]. - The qPCR kits for colorectal and gastric cancer will include three biomarkers and are expected to enter the IVD registration phase by 2027 [23][27]. - The company is focusing on diseases with high prevalence and lack of effective screening methods, aiming to expand its product offerings in the diagnostic market [13]. Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decline of 24.2% [44]. - The net profit for the period was RMB 27.3 million, down 26.3% year-on-year, primarily due to adjustments in sales strategy and fixed costs [44]. - For the six months ended June 30, 2025, the company reported revenue of RMB 81.3 million, a decrease of 24.2% compared to RMB 107.3 million for the same period in 2024 [46]. - The gross profit for the same period was RMB 60.1 million, down 13.6% year-over-year, with a gross margin of 74.0%, an increase of 9.1 percentage points from the previous year [48]. - Net profit for the six months ended June 30, 2025, was RMB 27.3 million, representing a decline of 26.3% compared to RMB 37.0 million in 2024 [56]. - The revenue from consumer-grade genetic testing services was RMB 75.9 million, while cancer screening services generated RMB 5.3 million, with the latter showing an impressive growth of 85.7% year-over-year [46]. - Total revenue for the six months ended June 30, 2025, was RMB 812.81 million, down from RMB 1,072.91 million in the same period of 2024 [59]. - The cost of sales decreased by 43.9% from RMB 376.73 million in 2024 to RMB 211.41 million in 2025, primarily due to lower revenue [62]. - Gross profit for the six months ended June 30, 2025, was RMB 601.40 million, with a gross margin of 74.0%, compared to RMB 696.18 million and 64.9% in 2024 [63]. - Other income increased by 22.5% from RMB 34 million in 2024 to RMB 42 million in 2025, mainly due to higher interest income [66]. - Selling and distribution expenses decreased by 23.4% from RMB 136 million in 2024 to RMB 104 million in 2025, reflecting reduced sales costs [67]. Research and Development - The company has a strong internal R&D team, with approximately 65% of members holding master's degrees or higher from prestigious institutions [33]. - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions [51]. - The company aims to develop low-cost, home-testing screening products to diversify its product portfolio and strengthen its market leadership [51]. - The cancer screening market is expected to grow, with the company focusing on increasing automation in production to reduce costs and improve product sensitivity and specificity [50]. - The company is in the early development stages of diagnostic kits for lung nodules and cervical cancer screening [40]. - The company has developed a non-invasive oral swab sampler to enhance accessibility and affordability of genetic testing for various demographics [41]. - The company collaborates with leading medical experts to accelerate clinical trials and enhance product reliability [34]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes and standards throughout the reporting period [138][139]. - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that are not yet effective, indicating a stable accounting policy environment [156]. - The company has assessed the impact of the revised Hong Kong Financial Reporting Standards and found no significant effect on its financial position or performance [154]. - The company operates as a single reportable operating segment, focusing on overall business performance rather than service-based divisions [159]. - The company has maintained the classification of its liabilities as current or non-current following the adoption of the revised standards, with no changes expected [154]. - The company is preparing to apply the new and revised Hong Kong Financial Reporting Standards upon their effective date, ensuring compliance and accuracy in financial reporting [156]. Shareholder Information and Equity - As of June 30, 2025, Dr. Yu Rong holds 18,795,135 shares (8.38%) and has an additional 22,000,000 shares (9.81%) through controlled entities [120]. - Ms. Guo Meiling owns 22,273,970 shares (9.93%) through controlled entities and 4,545,000 shares (2.03%) as beneficial ownership [120]. - Ms. Lin Lin has 9,975,311 shares (4.45%) through controlled entities and 13,636,000 shares (6.08%) as beneficial ownership [120]. - The total number of shares issued by the company as of June 30, 2025, is 224,300,200 shares [126]. - The company has granted a total of 19,181,000 restricted share units to several directors as of June 30, 2025 [126]. - The ownership structure indicates significant control by key executives, with Dr. Yu Rong and Ms. Guo Meiling having substantial stakes in the company [120]. - During the reporting period, the company repurchased a total of 3,834,000 shares at a total cost of HKD 32,897,016 [130]. - The share repurchase was aimed at increasing net asset value per share and earnings per share, authorized at the 2024 annual general meeting [132]. - The company raised approximately HKD 153.4 million from its global offering, with net proceeds allocated as follows: 30% for sales and marketing, 25% for R&D, 20% for testing capabilities and production capacity, 15% for investments and acquisitions, and 10% for working capital [134][135]. - As of June 30, 2025, the actual usage of the net proceeds was HKD 130.4 million, with HKD 23.0 million remaining for investments and acquisitions expected to be utilized by December 31, 2028 [135][136]. Operational Metrics - The company’s high-throughput testing platform can process up to 50,000 samples daily, providing cost-effective gene testing solutions [42]. - The current ratio as of June 30, 2025, was 15.2, significantly higher than 5.4 in 2024 [84]. - The company’s inventory increased to RMB 5,351,000 as of June 30, 2025, compared to RMB 4,609,000 as of December 31, 2024 [143]. - The company’s total assets less current liabilities stood at RMB 649,869,000 as of June 30, 2025, compared to RMB 647,837,000 as of December 31, 2024 [143]. - The group’s trade payables as of June 30, 2025, totaled RMB 25,376,000, slightly down from RMB 25,433,000 as of December 31, 2024 [176]. - The group’s research and development costs for the six months ended June 30, 2025, were RMB 8,151,000, a decrease from RMB 9,934,000 in 2024 [166].